CPT 81445: Solid Tumor Genomic Panel, 5–50 Genes
Commercial payers pay $643 on average nationally for this procedure.
CPT code 81445 describes a genomic sequence analysis panel performed on a patient tumor specimen to detect DNA (and when applicable RNA) alterations across 5 to 50 genes known to impact solid organ cancers; the service is a molecular pathology/genomic testing procedure typically performed in a clinical laboratory or pathology lab using next-generation sequencing workflows on tumor tissue or extracted nucleic acids.
For related coverage guidance, see recent payer policy updates: RTM Testing of Homocysteine Metabolism-Related Conditions, Multimarker Serum Testing Related to Ovarian Cancer, Genomic Profiling for Selecting Targeted Cancer Therapies.
Customize your policy alerts
Sign up for cpt 81445 policy alerts
Get alerted when payer policies referencing 81445 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
BUCA (average commercial) sits near a mean of $642.70 with a median of $540.20, framing the commercial market for CPT 81445 as moderate-to-high. Among the named payers, Cigna and Blue Cross Blue Shield show higher central tendencies (Cigna mean $752.60; BCBS median $597.00) while UnitedHealth Group and Aetna present lower medians ($320.10 and $478.00, respectively), creating a multi-modal distribution across commercial contracts.
Dispersion measured by the interquartile range (P75 minus P25) is widest for Cigna at $581.20 (P75 $872.30 minus P25 $319.10) and BCBS at $422.30 (P75 $711.60 minus P25 $469.30), indicating greater variability in negotiated commercial rates. UnitedHealth Group is the tightest at $335.20 (P75 $587.30 minus P25 $251.10), with Aetna intermediate at $380.70 (P75 $633.70 minus P25 $325.00); BUCA’s interquartile span is $304.60 (P75 $705.70 minus P25 $396.10), reflecting relatively concentrated commercial pricing around its median.